Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that James Patrick ... been elected to the Company,s Board of Directors, effective ... , Executive Chairman of CryoLife, stated, "Since joining the Company ... leader who is well positioned to maximize CryoLife,s potential. ...
(Date:10/22/2014)... SAN DIEGO , Oct. 21, 2014 /PRNewswire/ ... announced today the latest genomics research centers to ... the Salk Institute, the National Cancer Institute (NCI), ... National Sequencing Center). Before Irys, obtaining a comprehensive ... because next generation sequencing (NGS) does not deliver ...
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
... Inc. announced today that it has raised $19.2 million ... GBS Venture Partners and BioPacificVentures participated in the round. ... from additional investors in a second closing, scheduled for ... us to take essential steps for the development of ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... into a multi-year research collaboration agreement through the Stanford ... collaborative and innovative research projects in the early phases ... Dr. Paul Chew, Senior Vice President, U.S. Chief Science ...
Cached Medicine Technology:CoDa Therapeutics Closes $19 Million Series B Financing Round 2CoDa Therapeutics Closes $19 Million Series B Financing Round 3CoDa Therapeutics Closes $19 Million Series B Financing Round 4Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 2Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 3
(Date:10/22/2014)... 2014 Medical Solutions , ... happy to announce that our co-founder and CFO, ... Analysts’ Staffing 100 for 2014. Anderson was also ... influential people in the staffing industry,” in 2013.     ... 13th-largest healthcare staffing company in the U.S., was ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- The United ... arriving from Ebola-affected nations of West Africa land ... them for infection with the virus. In ... Johnson noted that 94 percent of air passengers ... at one of these five airports -- New ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... PUNTA GORDA, Fla., April 25 North ... closed on Cypress,Professional Center, 25097 Olympia Avenue, ... medical office building is located near,Charlotte Regional ... practice. The building is being converted to ...
... in partnership with,others to fight the malaria epidemic, ... treatable, malaria continues to devastate communities in,tropical regions ... World Health Organization (WHO), the malaria epidemic causes,debilitating ... and kills,more than one million people each year ...
... Thoratec,Corporation (Nasdaq: THOR ), a world ... support and restore failing hearts,today announced that it ... quarter of 2008 on Thursday, May 1., ... discuss its financial,results and operating activities to all ...
... funds ... clinic., New guide to low-income dental clinics in the ... teeth, gum,disease, extractions, root canals -- the very words give us ... to regularly visit our,dentists for preventive maintenance., Upper Willamette Valley ...
... helping doctors diagnose and treat lung cancer were ... Conference jointly organized by the European Society for ... the Study of Lung Cancer (IASLC) in Geneva, ... Friday 25th April, 16:30), Israeli researchers from Rosetta ...
... AX Series Delivers MyFluVaccine Portal a Next-generation Server Load ... Balancer Platform for Web Application Delivery, ... today,announced that FFF Enterprises, the nation,s largest distributor of ... Series Advanced Traffic Manager to provide a Web application,delivery ...
Cached Medicine News:Health News:Oaks Development Group Acquires Medical Office Building in Punta Gorda, Florida 2Health News:Global Health Progress Initiative Commemorates World Malaria Day 2Health News:Global Health Progress Initiative Commemorates World Malaria Day 3Health News:Thoratec Schedules First Quarter 2008 Conference Call, Webcast 2Health News:Smiles. Made Fresh Daily 2Health News:New genetic techniques to combat lung cancer 2Health News:FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager 2Health News:FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager 3
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Black multi-pinhole occluder...
6 inch hand held occlcuder with 49 holes...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: